MX2020008537A - Sales, formas cristalinas y metodos de produccion de las mismas. - Google Patents

Sales, formas cristalinas y metodos de produccion de las mismas.

Info

Publication number
MX2020008537A
MX2020008537A MX2020008537A MX2020008537A MX2020008537A MX 2020008537 A MX2020008537 A MX 2020008537A MX 2020008537 A MX2020008537 A MX 2020008537A MX 2020008537 A MX2020008537 A MX 2020008537A MX 2020008537 A MX2020008537 A MX 2020008537A
Authority
MX
Mexico
Prior art keywords
methods
salts
crystalline forms
production
methylmethanamine
Prior art date
Application number
MX2020008537A
Other languages
English (en)
Spanish (es)
Inventor
Shahla Jamzad
Haitao Zhang
Andrea Bauer
Nandkumar Nivritti Bhogle
Xiaoxia Chen
Robert Joseph Prytko
Kostas Saranteas
Harold Scott Wilkinson
Michael Joseph Sizensky
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of MX2020008537A publication Critical patent/MX2020008537A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2020008537A 2018-02-16 2019-02-15 Sales, formas cristalinas y metodos de produccion de las mismas. MX2020008537A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862710416P 2018-02-16 2018-02-16
PCT/US2019/018265 WO2019161238A1 (en) 2018-02-16 2019-02-15 Salts, crystal forms, and production methods thereof

Publications (1)

Publication Number Publication Date
MX2020008537A true MX2020008537A (es) 2021-01-08

Family

ID=65529921

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008537A MX2020008537A (es) 2018-02-16 2019-02-15 Sales, formas cristalinas y metodos de produccion de las mismas.
MX2022016230A MX2022016230A (es) 2018-02-16 2020-08-14 Clorhidrato de (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-nmetilm etanamina cristalino y formulaciones de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022016230A MX2022016230A (es) 2018-02-16 2020-08-14 Clorhidrato de (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-nmetilm etanamina cristalino y formulaciones de las mismas.

Country Status (15)

Country Link
US (4) US10815249B2 (https=)
EP (1) EP3752508A1 (https=)
JP (2) JP7453148B2 (https=)
KR (1) KR102746817B1 (https=)
CN (2) CN112135827B (https=)
AU (2) AU2019222491B2 (https=)
CA (1) CA3091292A1 (https=)
EA (1) EA202091945A1 (https=)
IL (3) IL285739B2 (https=)
MX (2) MX2020008537A (https=)
MY (1) MY208150A (https=)
PH (1) PH12020551256A1 (https=)
SG (1) SG11202007823PA (https=)
UA (1) UA130249C2 (https=)
WO (1) WO2019161238A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106883246B (zh) 2009-12-04 2020-05-29 桑诺维恩药品公司 多环化合物及其使用方法
CA3032141A1 (en) 2016-07-29 2018-02-01 Vadim ALEXANDROV Compounds and compositions and uses thereof
IL268694B2 (en) 2017-02-16 2023-10-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
EA202091945A1 (ru) 2018-02-16 2021-01-18 Суновион Фармасьютикалз Инк. Соли, кристаллические формы и способы их получения
CN118576586A (zh) 2018-12-06 2024-09-03 住友制药美国公司 治疗神经和精神疾病的方法
CN115734785A (zh) * 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症
US12492213B2 (en) 2020-09-16 2025-12-09 Assia Chemical Industries Ltd. Solid state forms of sep-363856 and process for preparation thereof
WO2023049721A1 (en) 2021-09-23 2023-03-30 Sunovion Pharmaceuticals Inc. Methods of treating metabolic disorders
EP4580615A1 (en) 2022-08-30 2025-07-09 Sumitomo Pharma America, Inc. Ulotaront for the adjuvant treatment of major depressive disorder
AU2023358704A1 (en) 2022-10-13 2025-05-29 Sumitomo Pharma America, Inc. Methods of reducing physical dependence to neuropsychiatric treatments
TW202421114A (zh) 2022-10-28 2024-06-01 美商住友製藥美國公司 治療焦慮及相關病狀之方法
CN120187422A (zh) 2022-11-15 2025-06-20 住友制药美国公司 使用ulotaront转换神经精神病学药物的方法
WO2025175067A1 (en) 2024-02-16 2025-08-21 Sumitomo Pharma America, Inc. Methods of administering the neuropsychiatric medication ulotaront based on renal impairment
TW202600129A (zh) 2024-02-23 2026-01-01 美商住友製藥美國公司 烏洛托隆（ulotaront）鹽酸鹽的製造方法

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036842A (en) 1972-05-16 1977-07-19 American Home Products Corporation Process for preparing polycyclic heterocycles having a pyran ring
US4021451A (en) 1972-05-16 1977-05-03 American Home Products Corporation Process for preparing polycyclic heterocycles having a pyran ring
US4021452A (en) 1975-04-23 1977-05-03 American Cyanamid Company 2,5-Dihydro-2,5-dialkoxyfuran derivatives
US4127665A (en) 1978-01-18 1978-11-28 Pfizer Inc. Thienohydantoin derivatives
FR2459239A1 (fr) 1979-06-20 1981-01-09 Logeais Labor Jacques Nouveaux derives amines du benzothiazole, leur procede de preparation et leur application en therapeutique
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
CA1336909C (en) 1988-03-16 1995-09-05 Vittorio Vecchietti Heterocyclic derivatives
DE3827727A1 (de) 1988-08-16 1990-02-22 Boehringer Ingelheim Kg Anellierte tetrahydropyridinessigsaeurederivate, verfahren zu deren herstellung und verwendung solcher verbindungen zur kardioprotektion
GB8824400D0 (en) 1988-10-18 1988-11-23 Glaxo Group Ltd Chemical compounds
EP0368175A1 (de) 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
GB8827479D0 (en) 1988-11-24 1988-12-29 Zambeletti Spa L Novel compounds
EP0416740A3 (en) 1989-08-08 1991-08-28 Beecham Group P.L.C. Novel compounds with renin-inhibiting activity
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
GB8927872D0 (en) 1989-12-08 1990-02-14 Beecham Group Plc Pharmaceuticals
ZA912744B (en) 1990-03-23 1992-02-26 Zambeletti Spa L Pharmaceuticals
JPH049367A (ja) 1990-04-26 1992-01-14 Zeria Pharmaceut Co Ltd アリールアルカノイル誘導体，該化合物の製造中間体及びそれらを含有する医薬
GB9018139D0 (en) 1990-08-17 1990-10-03 Pfizer Ltd Therapeutic agents
NZ240155A (en) 1990-10-29 1992-10-28 Ishihara Sangyo Kaisha Heterocyclyl acyl and (hexahydro) indanyl acyl substituted hydrazine derivatives, preparation thereof and pesticidal compositions
DE4104257A1 (de) 1991-02-13 1992-08-20 Boehringer Ingelheim Kg Verwendung von anellierten tetrahydropyridinessigsaeurederivaten fuer die behandlung neurologischer erkrankungen
GB9104839D0 (en) 1991-03-07 1991-04-17 Zambeletti Spa L Novel compounds
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
PH31294A (en) 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
JP3223277B2 (ja) 1992-04-10 2001-10-29 カシオ計算機株式会社 楽音制御装置
FR2692264B1 (fr) 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
IT1255178B (it) 1992-06-26 1995-10-20 Pierrel Spa N(eter0)-aril-n(etero)-tetralinalchil piperazine aventi attivita' serotoninergica,dopaminergica e adrenergica
EP0600836B1 (de) 1992-12-02 1998-08-05 Novartis AG Selektiv-herbizides Mittel
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
JP3163068B2 (ja) 1993-12-27 2001-05-08 日本建工株式会社 野縁取付け金具
FR2723091B1 (fr) 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
WO1999046267A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
HUP0104984A3 (en) 1998-03-12 2003-07-28 Ontogen Corp Carlsbad Modulators of protein tyrosine phosphatases (ptpases) pharmaceutical compositions containing them and their use
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
WO1999046237A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
TR200101649T2 (tr) 1998-12-14 2001-10-22 Fujisawa Pharmaceutical Co., Ltd. Piperazin türevleri.
DE60028538T2 (de) 1999-01-19 2007-06-21 Neurosearch A/S Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
US6313309B1 (en) 1999-04-05 2001-11-06 Ortho-Mcneil Pharmaceutical, Inc. 4-thionaphthyl—1H—imidazoles which are usefulα22-adrenoceptoR agonists/ antagonists
WO2000068230A1 (en) 1999-05-05 2000-11-16 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors
EP1214060A2 (en) 1999-09-10 2002-06-19 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
AU6985300A (en) 1999-09-10 2001-04-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
WO2001032610A1 (en) 1999-10-29 2001-05-10 Kaken Pharmaceutical Co., Ltd. Urea derivative, process for producing the same, and medicine containing the urea derivative
AR030537A1 (es) 1999-11-05 2003-08-27 Abbott Lab Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
US20020049223A1 (en) 1999-11-05 2002-04-25 Elmore Steven W. Quinoline and naphthyridine carboxylic acid antibacterials
WO2002012189A1 (en) 2000-08-09 2002-02-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
JP2002179678A (ja) 2000-09-12 2002-06-26 Sankyo Co Ltd キノリジン化合物
AU2001286191A1 (en) 2000-09-12 2002-03-26 Sankyo Company, Limited Quinolizine derivatives
DOP2002000386A (es) 2001-05-30 2002-12-15 Warner Lambert Co Agentes antibacterianos
WO2002102387A1 (en) 2001-06-18 2002-12-27 H. Lundbeck A/S Treatment of neuropathic pain
WO2002102793A2 (en) 2001-06-19 2002-12-27 Warner-Lambert Company Llc Quinazolinediones as antibacterial agents
WO2003006455A1 (en) 2001-07-11 2003-01-23 Eli Lilly And Company Pharmaceutical compounds with serotonin receptor activity
US20040180883A1 (en) 2001-07-11 2004-09-16 Jeremy Gilmore Pharmaceutical compounds with serotonin receptor activity
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
JP2003261566A (ja) 2002-03-11 2003-09-19 Sankyo Co Ltd キノリジンを含有する医薬
TW200306783A (en) 2002-04-29 2003-12-01 Fmc Corp Pesticidal heterocycles
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
WO2004035812A2 (en) 2002-10-16 2004-04-29 Isis Innovation Limited Asparaginyl hydroxylases and modulators thereof
KR100678800B1 (ko) 2002-11-21 2007-02-05 화이자 프로덕츠 인코포레이티드 3-아미노-피페리딘 유도체 및 그의 제조 방법
EP1587482A4 (en) 2003-01-31 2010-08-25 Technion Res & Dev Foundation INFLAMMATORY COMPOSITIONS AND ITS USES
EP2527326B1 (en) 2003-03-07 2014-10-08 Santen Pharmaceutical Co., Ltd Novel compounds having 4-pyridylalkylthio group as substituent
JP2004269449A (ja) 2003-03-11 2004-09-30 Ishihara Sangyo Kaisha Ltd ベンズアミド誘導体、それらの製造方法及びそれらを含有する有害生物防除剤
US20070154534A1 (en) 2003-03-12 2007-07-05 Sheitman Brian B Use of secretin in the treatment of schizophrenia
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
JP2006522109A (ja) 2003-03-31 2006-09-28 大正製薬株式会社 新規なキナゾリン誘導体及びそれらの使用に関連する治療方法
JP2005145859A (ja) 2003-11-13 2005-06-09 Nippon Steel Chem Co Ltd 脱水素化方法及び芳香族複素環化合物の製造方法
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2007529422A (ja) 2004-01-29 2007-10-25 エリクシアー ファーマシューティカルズ， インコーポレイテッド 抗ウイルス治療
DE102004004974A1 (de) 2004-01-31 2005-08-18 Aventis Pharma Deutschland Gmbh Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
KR100553398B1 (ko) 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
RU2007107177A (ru) 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
SE0401970D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
JP2006117568A (ja) 2004-10-20 2006-05-11 Mitsubishi Pharma Corp チオフェン環を有する新規アミド誘導体及びその医薬としての用途
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
EP1856126A2 (en) 2005-02-17 2007-11-21 Wyeth a Corporation of the State of Delaware Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
CN101203512A (zh) 2005-04-22 2008-06-18 第一三共株式会社 杂环化合物
EP1896515A4 (en) 2005-06-27 2010-03-10 Du Pont ELECTRICALLY CONDUCTIVE POLYMER COMPOSITIONS
WO2007001939A1 (en) 2005-06-27 2007-01-04 Janssen Pharmaceutica N.V. Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities
JP2009505948A (ja) 2005-07-11 2009-02-12 デブジェン エヌブイ キナーゼ阻害剤としてのアミド誘導体
US8846742B2 (en) 2006-02-14 2014-09-30 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
AU2007222069A1 (en) 2006-02-21 2007-09-13 Ampla Pharmaceuticals Inc. CB1 antagonists and inverse agonists
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
JPWO2007126041A1 (ja) 2006-04-28 2009-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゾイソオキサゾール化合物
EP2069326B1 (en) 2006-10-04 2015-03-18 Merck Sharp & Dohme Corp. Bicyclic and tricyclic derivatives as thrombin receptor antagonists
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2008058342A1 (en) 2006-11-15 2008-05-22 Genetic Technologies Limited Compounds, compositions and methods for controlling invertebrate pests
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
US7598417B2 (en) 2007-04-12 2009-10-06 Allergan, Inc. Substituted fluoroethyl ureas as alpha 2 adrenergic agents
EP1982987A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Spiro-pyrano-pyrazole derivatives
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
ES2469824T3 (es) 2007-11-21 2014-06-20 Janssen Pharmaceutica N.V. Espiropiperidinas para su uso como inhibidores de la triptasa
US7973051B2 (en) 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
JPWO2009072621A1 (ja) 2007-12-07 2011-04-28 日産化学工業株式会社 置換ジヒドロアゾール化合物及び有害生物防除剤
WO2009085256A1 (en) 2007-12-27 2009-07-09 Panacos Pharmaceuticals, Inc. Anti-hiv compounds
CN101759710B (zh) 2008-10-06 2011-10-05 山东轩竹医药科技有限公司 含有取代的氮杂环的头孢菌素衍生物
US9776963B2 (en) 2008-11-10 2017-10-03 The Trustees Of The University Of Pennsylvania Small molecule CD4 mimetics and uses thereof
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
WO2011036889A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
ES2436241T3 (es) 2009-11-16 2013-12-27 Eli Lilly And Company Compuestos de espiropiperidina como antagonistas de receptor oral-1
CN106883246B (zh) 2009-12-04 2020-05-29 桑诺维恩药品公司 多环化合物及其使用方法
KR101778320B1 (ko) 2009-12-28 2017-09-13 잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 1,3,4-옥사디아졸-2-카르복사미드 화합물
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
US8895608B2 (en) 2010-04-23 2014-11-25 Kineta, Inc. Sulfonamide anti-viral compounds
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
CN102731574B (zh) 2011-03-30 2016-03-02 中国人民解放军军事医学科学院毒物药物研究所 噻吩并吡啶类α-胺基苄基膦酸酯、其制备方法及用途
WO2013010453A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Chemoking receptor antagonists
JP6333382B2 (ja) 2014-07-23 2018-05-30 シャープ株式会社 表示装置およびその駆動方法
IL268694B2 (en) 2017-02-16 2023-10-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
JP2021513972A (ja) 2018-02-16 2021-06-03 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 社会的機能障害の治療方法
EA202091945A1 (ru) 2018-02-16 2021-01-18 Суновион Фармасьютикалз Инк. Соли, кристаллические формы и способы их получения
CN118576586A (zh) 2018-12-06 2024-09-03 住友制药美国公司 治疗神经和精神疾病的方法
CN115734785A (zh) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症
US12492213B2 (en) 2020-09-16 2025-12-09 Assia Chemical Industries Ltd. Solid state forms of sep-363856 and process for preparation thereof
WO2023049721A1 (en) 2021-09-23 2023-03-30 Sunovion Pharmaceuticals Inc. Methods of treating metabolic disorders

Also Published As

Publication number Publication date
US20240425516A1 (en) 2024-12-26
JP7453148B2 (ja) 2024-03-19
US20220402937A1 (en) 2022-12-22
JP2021513975A (ja) 2021-06-03
EA202091945A1 (ru) 2021-01-18
AU2019222491B2 (en) 2023-01-12
UA130249C2 (uk) 2025-12-31
CN118406063A (zh) 2024-07-30
US10815249B2 (en) 2020-10-27
CA3091292A1 (en) 2019-08-22
EP3752508A1 (en) 2020-12-23
US20190256525A1 (en) 2019-08-22
NZ767293A (en) 2024-10-25
PH12020551256A1 (en) 2021-04-19
IL324126A (en) 2025-12-01
IL276692A (en) 2020-09-30
SG11202007823PA (en) 2020-09-29
AU2023202174B2 (en) 2025-01-23
JP7811230B2 (ja) 2026-02-04
MY208150A (en) 2025-04-18
IL285739B1 (en) 2025-11-01
MX2022016230A (es) 2023-02-02
AU2023202174A1 (en) 2023-05-04
AU2019222491A1 (en) 2020-09-10
US11440921B2 (en) 2022-09-13
US11987591B2 (en) 2024-05-21
US20210053983A1 (en) 2021-02-25
CN112135827A (zh) 2020-12-25
KR102746817B1 (ko) 2024-12-24
KR20200122345A (ko) 2020-10-27
JP2024063208A (ja) 2024-05-10
WO2019161238A1 (en) 2019-08-22
CN112135827B (zh) 2024-01-12
IL285739B2 (en) 2026-03-01
IL276692B (en) 2021-09-30
IL285739A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2020008537A (es) Sales, formas cristalinas y metodos de produccion de las mismas.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2021004191A (es) Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
MX2021015936A (es) Metodos para preparar acido bempedoico y composiciones del mismo.
TN2020000001A1 (en) Carboxamides as modulators of sodium channels
PE20160287A1 (es) Inhibidores cristalinos de bromodominos
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
UY37379A (es) Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades
WO2017210545A8 (en) Potassium channel modulators
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CR8778A (es) Revestimientos de azucar y metodos para estos
ECSP21030482A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
CO2017004517A2 (es) Inhibidores de las tirosina cinasas de bruton derivados de la 2, 3, 4, 9-tetrahidro-ih-carbazol-8- carboxamida y 9h-carbazol-l-carboxamida, composiciones que los comprenden y metodos de elaboration
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
CO2017012622A2 (es) Moduladores alostéricos positivos del receptor muscarínico m2
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
MX2016015961A (es) Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas.
EP4585213A3 (en) Amlodipine formulations
CO2020004407A2 (es) Formulaciones de espora de nutriente y usos de las mismas
CO2019014831A2 (es) Nuevas formulaciones orales de belinostat
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida